Related Experiment Video
Updated: Jan 30, 2026
07:54
Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
Published on: December 15, 2011
13.5K
[Research progress of hepatitis C in 2018]
1Hepatology Department, Peking University People's Hospital, Peking University Hepatology Institute, Beijing 100044, China.
Summary
Direct-acting antiviral agents (DAAs) have made hepatitis C treatment simpler and more accessible globally. Research in 2018 shifted focus to improving treatment accessibility and managing special populations.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Major direct-acting antiviral agents (DAAs) are approved, enabling pan-genotypic hepatitis C treatment.
- Global recommendations favor simple monitoring strategies for hepatitis C.
- Hepatitis C research in 2018 prioritized treatment accessibility over novel regimens.
Purpose of the Study:
- To review the current landscape of direct-acting antiviral agents for hepatitis C.
- To highlight the progress in making hepatitis C treatments more accessible.
- To identify emerging research areas in hepatitis C management.
Main Methods:
- Literature review of approved direct-acting antiviral agents.
- Analysis of research trends in hepatitis C treatment accessibility.
- Examination of clinical trial progress and regulatory approvals.
Main Results:
- Pan-genotypic DAAs are globally recommended, simplifying treatment.
- Increased accessibility and affordability of hepatitis C treatment through collaborative efforts.
- A growing number of DAAs are approved and in clinical trials, expanding treatment options.
- Emerging focus on managing hepatitis C in pregnant women, children, and fetuses.
Conclusions:
- Hepatitis C treatment has significantly advanced with DAAs, improving global outcomes.
- Efforts to enhance treatment accessibility are yielding positive results.
- Future research will likely address the management of hepatitis C in vulnerable populations.
Related Concept Videos
02:07Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
274
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
274
01:21Hepatic Portal System
5.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.8K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
243
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
243
03:03mTOR Signaling and Cancer Progression
4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.8K
01:16Hepatic Drug Excretion: Influencing Factors
564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564